Sun Pharma Inds.
Ticker > Company >

Sun Pharma Inds. share price

Sun Pharmaceutical Industries Ltd.

NSE: SUNPHARMA BSE: 524715 SECTOR: Pharmaceuticals & Drugs  438k   2k   539

1767.20
-14.10 (-0.79%)
NSE: 08 May 4:00 PM

Price Summary

Today's High

₹ 1788.9

Today's Low

₹ 1755

52 Week High

₹ 1960.35

52 Week Low

₹ 1377.2

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyPoor
The company seems highly inefficient in case of asset management.
FinancialsVery Stable
The company possesses stable growth history and manageable debt.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

₹ 424010.48 Cr.

Enterprise Value

₹ 434718.7 Cr.

No. of Shares

239.93 Cr.

P/E

134.62

P/B

17.12

Face Value

₹ 1

Div. Yield

0.76 %

Book Value (TTM)

₹  103.25

CASH

₹ 338.39 Cr.

DEBT

₹ 11046.61 Cr.

Promoter Holding

54.48 %

EPS (TTM)

₹  13.13

Sales Growth

-2.58%

ROE

12.05 %

ROCE

12.81%

Profit Growth

69.05 %

Add Your Ratio

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Brands

These are the brands of Sun Pharmaceutical Industries Ltd.

Molxvir Gloeye Prazopress Pantocid Predmet Garlic Pearls REVITAL VOLINI PEPFIZ Diamox Deslor Cepodem Colvac Livcare Montek Mox CV Nexito Abzorb Faringosept

Index Presence

The company is present in 48 Indices.

NIFTY100WEIGHT

Nifty100 Equal Weight
30574.4
  -460.399999999998 (-1.48349594648587%)

NIFTYEQWGT

NIFTY50 Equal Weight
29964.8
  -273.950000000001 (-0.905956760778803%)

NFTY200MOM30

Nifty200 Momentum 30
29058.85
  -417.700000000001 (-1.41705864492283%)

NFTALLO30

NIFTY Alpha Low-Volatility 30
25854
  -350.5 (-1.33755652655079%)

NIFTY100

Nifty 100
24678
  -209.200000000001 (-0.84059275450834%)

NIFTY

Nifty 50
24273.8
  -140.600000000002 (-0.575889638901639%)

NIFTYLOWVOL

Nifty Low Volatility 50
24264.8
  -260.549999999999 (-1.06237015985501%)

NIFTY500

Nifty 500
21843.05
  -229.400000000001 (-1.0393046535387%)

NFTALQVL30

NIFTY Alpha Quality Low-Volatility 30
21265.45
  -308.049999999999 (-1.42790924050339%)

NIFTYPHARMA

Nifty Pharma
21115.05
  -347.400000000001 (-1.61864092869175%)

NFTALQLV30

NIFTY Alpha Quality Value Low-Volatility 30
19447.05
  -187.900000000001 (-0.956967040914292%)

NT100LOW30

Nifty100 Low Volatility 30
19269.25
  -135 (-0.695723874924303%)

NFTQTLO30

NIFTY Quality Low-Volatility 30
16657.6
  -143.900000000001 (-0.856471148409377%)

NIF500LGMIDSML

Nifty500 LargeMidSmall Equal-Cap Weighted Index
16343.95
  -209.5 (-1.26559720179177%)

NIFTYLGEMID250

NIFTY LargeMidcap 250
15195
  -200.85 (-1.3045723360516%)

NY500MUL50:25:25

Nifty500 Multicap 50:25:25
14979.2
  -175.699999999999 (-1.15936099875287%)

NY500MUL50:30:20

Nifty500 Multicap India Manufacturing 50:30:20
14116.15
  -224.200000000001 (-1.56342069754225%)

NIFTYHEALTH

Nifty Healthcare Index
13696.75
  -272.049999999999 (-1.94755455014031%)

NIFTYMFG

Nifty Manufacturing
13359.75
  -231.049999999999 (-1.70004709067898%)

NIFTY200

Nifty 200
13326.75
  -137.65 (-1.02232553994236%)

NFT500EQUAL

Nifty 500 Equal Weight
12836.65
  -161.9 (-1.24552353916398%)

NIFTYTOTALMCAP

Nifty Total Market index
12259.15
  -127.9 (-1.03252994054274%)

NI15

NI15
11116.35
  -151.949999999999 (-1.3484731503421%)

NIFTY20EW

Nifty Top 20 Equal Weight Index
8974.8
  -36.7000000000007 (-0.407257393330751%)

NIFTY100ESG

NIFTY100 ESG
4680.05
  -53.0999999999995 (-1.12187443879868%)

SENSEX

S&P Bse Sensex
80334.81
  -411.970000000001 (-0.510199911377274%)

SENSEXEW

Bse Sensex Equal Weight
77317.45
  -484.190000000002 (-0.622339066374444%)

BSE HC

S&P Bse Healthcare
41287.94
  -691.909999999996 (-1.64819550331885%)

BSE500

S&P Bse 500
34339.7
  -382.5 (-1.10160070502445%)

SS6535

BSE Sensex Sixty 65:35
32730.04
  -304.220000000001 (-0.920922702672922%)

SNSX60

BSE Sensex Sixty
32617.76
  -246.119999999999 (-0.748907311005276%)

SNSX50

S&P Bse Sensex50
25334.72
  -159.209999999999 (-0.624501597046823%)

BSE100

S&P Bse 100
25217.75
  -243.580000000002 (-0.956666442797771%)

200EQW

BSE 200 Equal Weight
12079.06
  -209.690000000001 (-1.70635744074865%)

BSE200

S&P Bse 200
10863.7
  -119.699999999999 (-1.08982646539322%)

S&P LARGEMIDCAP

S&P Bse Large MidCap
10319.66
  72.75 (0.709970127579918%)

LMI250

S&P Bse 250 LargeMidCap
10271.22
  -113.050000000001 (-1.08866583784899%)

BSE1000

Bse 1000
10185.63
  -112.6 (-1.09339177703354%)

ALLCAP

S&P Bse Allcap
10130.99
  38.3799999999992 (0.380278243189802%)

LRGCAP

S&P Bse LargeCap
9269.71
  -87.6100000000006 (-0.936272351485257%)

BSE100LARGECAPTMC

S&P Bse 100 LargeCap TMC
8896.08
  -81.9600000000009 (-0.912894128339825%)

GREENEX

S&P Bse Greenex
7827.5
  33.6300000000001 (0.431492955361068%)

CARBONEX

S&P Bse Carbonex
4344.48
  15.7799999999997 (0.364543627417002%)

SPBSMOIP

S&P Bse Momentum
2020.69
  -42.2599999999998 (-2.04852274655226%)

SPBSLVIP

S&P Bse Low Volatility
1767.96
  -12.5799999999999 (-0.706527233311238%)

MFG

S&P Bse Manufacturing
985.7
  -9.31999999999994 (-0.936664589656488%)

S&PDIVSTABLE

S&P Bse Dividend Stability
952.42
  -13.6900000000001 (-1.41702290629432%)

ESG100

S&P Bse 100 ESG Index
406.94
  -3.43000000000001 (-0.835831079269933%)

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.

PE Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

PB Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year-2.58%
3 Year12.83%
5 Year14.5%

Profit Growth

1 Year69.05%
3 Year50.26%
5 Year28.47%

ROE%

1 Year12.05%
3 Year6.22%
5 Year7.11%

ROCE %

1 Year12.81%
3 Year7.43%
5 Year7.59%

Debt/Equity

0.4662

Price to Cash Flow

-1450.01

Interest Cover Ratio

5.3996

CFO/PAT (5 Yr. Avg.)

1.02798134655305

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Mar 2025 54.48 0.88
Dec 2024 54.48 0.69
Sep 2024 54.48 0.79
Jun 2024 54.48 1.07
Mar 2024 54.48 2.05
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has shown a good profit growth of 50.2647359659939% for the Past 3 years.
  • The Company has been maintaining an effective average operating margins of 21.7481220234021% in the last 5 years.
  • The company has an efficient Cash Conversion Cycle of 23.2817 days.
  • Company has a healthy liquidity position with current ratio of 3.3553.
  • The company has a high promoter holding of 54.48%.

 Limitations

  • The company has shown a poor revenue growth of 12.8279198272913% for the Past 3 years.
  • Company has a poor ROE of 6.21886280846473% over the past 3 years.
  • Promoter pledging has increased from 0.686233877219073% to 0.88% in 1 quarter.
  • Company has negative cash flow from operations of -292.42.
  • The company is trading at a high PE of 134.62.
  • The company is trading at a high EV/EBITDA of 71.8252.

Quarterly Result (All Figures in Cr.)

PARTICULARS Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024
Net Sales 5073.75 5639.14 4498.07 5127.71 6191.81
Total Expenditure 3866.43 3745.61 3737 3917.42 4488.34
Operating Profit 1207.32 1893.53 761.07 1210.29 1703.47
Other Income 228.48 118.88 82.74 214.63 68.39
Interest 214.92 217.59 216.08 243.75 215.96
Depreciation 399.6 393.04 369.81 285.53 290.97
Exceptional Items -69.81 0 0 0 0
Profit Before Tax 751.47 1401.78 257.92 895.64 1264.93
Tax 30.16 534.18 20.1 32.35 83.88
Profit After Tax 721.31 867.6 237.82 863.29 1181.05
Adjusted EPS (Rs) 3.01 3.62 0.99 3.6 4.92

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Net Sales 12531.93 14116.05 15585.98 20812.14 20275.17
Total Expenditure 9820.28 11859.04 12917.42 14389.54 14775.28
Operating Profit 2711.65 2257.01 2668.56 6422.6 5499.89
Other Income 1510.92 192.07 1196.88 329.29 553.48
Interest 408.01 267.52 388.1 472.18 784.08
Depreciation 561.56 1236.43 1349.95 1600.87 1600.62
Exceptional Items 0 -89.56 -1820.53 -2937.79 -219.02
Profit Before Tax 3253 855.57 306.86 1741.05 3449.65
Tax 41.86 13.17 406.85 50.33 591.47
Net Profit 3211.14 842.4 -99.99 1690.72 2858.18
Adjusted EPS (Rs.) 13.38 3.51 -0.42 7.05 11.91

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity and Liabilities
Share Capital 239.93 239.93 239.93 239.93 239.93
Total Reserves 24156.29 26698.54 24348.02 23508.43 23454.47
Borrowings 1256.69 5300.02 4865.64 7586.73 11036.01
Other N/C liabilities 1890.56 1928.04 1498.21 1622.92 2809.79
Current liabilities 11203.74 9951.33 10105.83 8365.44 4444.51
Total Liabilities 38747.21 44117.86 41057.63 41324.07 41985.34
Assets
Net Block 5228.74 9668.79 9712.78 8711.67 7736.74
Capital WIP 384.35 459.2 358.94 328.87 388.24
Intangible WIP 212.26 631.18 469.7 524.04 377.87
Investments 16966.65 15506.2 15355.83 12412.98 12429.97
Loans & Advances 4013.14 5120.85 5451.94 2866.3 6077.91
Other N/C Assets 0.95 1.56 4.69 36.46 62.07
Current Assets 11941.12 12730.08 9703.75 16443.75 14912.54
Total Assets 38747.21 44117.86 41057.63 41324.07 41985.34
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Profit from operations 3253 855.57 306.86 1741.05 3449.65
Adjustment -217.09 1717.87 1266.29 4823.4 1768.91
Changes in Assets & Liabilities -1393 -2752.28 3903.67 -5625.38 -5169.11
Tax Paid -337.06 -237.67 2159.54 -431.99 -341.87
Operating Cash Flow 1305.85 -416.51 7636.36 507.08 -292.42
Investing Cash Flow 1483.04 1452.47 -2697.04 -685.64 -265.35
Financing Cash Flow -2871.15 -999.73 -4870.85 169.31 473.95
Net Cash Flow -82.26 36.23 68.47 -9.25 -83.82

Corporate Actions

Investors Details

PARTICULARS Mar 2024% Jun 2024% Sep 2024% Dec 2024% Mar 2025%
promoters 54.48 54.48 54.48 54.48 54.48
aalok dilip shanghvi 0.12 0.12 0.12 0.12 0.12
aditya medisales limited 1.67 1.67 1.67 1.67 1.67
dilip.s.shanghvi - - 9.60 9.60 9.60
raksha sudhir valia - - - - 1.20
shanghvi family & friends... 0.05 0.05 0.05 0.05 0.05
shanghvi finance private ... 40.30 40.30 40.30 40.30 40.30
sudhir v. valia 0.60 0.60 0.60 0.60 0.60
unimed investments limite... 0.43 0.43 0.43 0.43 0.43
vibha dilip shanghvi 0.37 0.37 0.37 0.37 0.37
vidhi dilip shanghvi 0.12 0.12 0.12 0.12 0.12
raksha s.valia 1.20 1.20 1.20 1.20 -
dilip s. shanghvi - 9.60 - - -
dilip. s. shanghvi 9.60 - - - -
PARTICULARS Mar 2024% Jun 2024% Sep 2024% Dec 2024% Mar 2025%
investors 45.52 45.52 45.52 45.52 45.52
hdfc trustee company ltd.... - 1.01 1.03 1.12 1.13
icici prudential value di... 3.15 4.06 3.40 3.26 3.35
investor education and pr... 0.12 - 0.11 - 0.12
lakshdeep investments & f... - 1.02 - 1.02 1.02
life insurance corporatio... 2.92 3.10 3.14 2.93 3.04
llp 0.27 0.26 0.26 0.26 0.26
nps trust- a/c hdfc pensi... - - - 1.18 1.20
sbi nifty 50 etf 2.27 2.10 2.18 2.19 2.04
government pension fund g... 1.04 - 1.01 1.01 -
investor education and pr... - 0.11 - 0.12 -
lakshdeep investments & f... - - 1.02 - -
nps trust- a/c hdfc pensi... - 1.19 1.17 - -

Annual Reports

Ratings & Research Reports

Company Presentations

Company News

Sun Pharmaceutical Industries informs about press release 24 Apr, 10:08 AM Sun Pharmaceutical Industries’ arm recalls around 13,700 bottles of Gabapentin capsules 14 Apr, 11:43 AM US court lifts restrictions on Sun Pharma launching autoimmune disorder drug 11 Apr, 11:53 AM Sun Pharma launches Fexuprazan tablets 40 mg in India 7 Apr, 10:47 AM Sun Pharmaceutical Industries informs about press release 7 Apr, 9:58 AM Sun Pharmaceutical Industries informs about change in directorate 2 Apr, 4:53 PM Sun Pharmaceutical Industries’ arm acquires Antibe Therapeutics Inc. 18 Mar, 6:03 PM Sun Pharma’s arm recalls 9,840 bottles of Morphine Sulfate extended-release tablets in US 17 Mar, 4:20 PM Sun Pharma to acquire Checkpoint Therapeutics 10 Mar, 10:17 AM Sun Pharmaceutical Industries informs about press release 10 Mar, 9:20 AM Sun Pharmaceutical Industries informs about press release 17 Feb, 5:28 PM Sun Pharmaceutical included in S&P Global Sustainability Yearbook 2025 17 Feb, 3:23 PM Sun Pharmaceutical reports 14% surge in Q3 consolidated net profit 31 Jan, 5:18 PM Sun Pharma Inds. - Quaterly Results 31 Jan, 3:12 PM Sun Pharma Inds. - Quaterly Results 31 Jan, 3:12 PM Sun Pharma Inds. - Quaterly Results 31 Jan, 3:12 PM Sun Pharma to acquire 100% stake in Antibe 16 Jan, 2:44 PM Sun Pharmaceutical Industries informs about disclosure 16 Jan, 1:01 PM Sun Pharma to sell 100% shares in Sun Pharma Japan Technical Operations 1 Jan, 10:22 AM Sun Pharmaceutical Industries informs about newspaper publication 17 Dec, 5:19 PM Sun Pharmaceutical Industries informs about disclosure 6 Nov, 5:31 PM Sun Pharmaceutical Industries reports 28% rise in Q2 consolidated net profit 28 Oct, 5:36 PM Sun Pharma Inds. - Quaterly Results 28 Oct, 2:38 PM Sun Pharma Inds. - Quaterly Results 28 Oct, 2:38 PM Sun Pharma Inds. - Quaterly Results 28 Oct, 2:38 PM Sun Pharmaceutical Industries informs about press release 1 Oct, 2:24 PM Sun Pharma inks agreement to commercialize Philogen’s specialty product Fibromun 1 Oct, 10:10 AM Sun Pharma launches Tedizolid Phosphate tablets in India 23 Aug, 4:14 PM Sun Pharmaceutical Industries informs about disclosure 20 Aug, 5:22 PM Sun Pharmaceutical Industries reports 40% rise in Q1 consolidated net profit 1 Aug, 5:30 PM Sun Pharma Inds. - Quaterly Results 1 Aug, 2:11 PM Sun Pharma Inds. - Quaterly Results 1 Aug, 2:11 PM Sun Pharma Inds. - Quaterly Results 1 Aug, 2:11 PM Sun Pharmaceutical gets USFDA’s nod for LEQSELVI tablets 26 Jul, 2:25 PM Sun Pharmaceutical Industries informs about press release 26 Jul, 9:51 AM Sun Pharmaceutical Industries informs about press release 16 Jul, 5:26 PM Sun Pharmaceutical completes merger of Taro Pharmaceutical Industries 24 Jun, 5:50 PM Sun Pharmaceutical Industries informs about press release 21 Jun, 9:47 AM Sun Pharma enters into patent licensing agreement with Takeda Pharmaceutical 21 Jun, 9:22 AM Sun Pharmaceutical Industries gets warning letter from USFDA for Dadra facility 20 Jun, 9:50 AM Sun Pharmaceutical Industries informs about press release 14 Jun, 5:10 PM Sun Pharmaceutical Industries informs about analyst meet 11 Jun, 11:58 AM Sun Pharma to acquire 9.6% stake in HaystackAnalytics 7 Jun, 9:20 AM Sun Pharmaceutical Industries informs about disclosure 4 Jun, 2:30 PM Sun Pharma’s arm recalls 35,069 bottles of Xelpros 31 May, 2:29 PM Sun Pharmaceutical Industries reports 34% rise in Q4 consolidated net profit 23 May, 5:19 PM Sun Pharma Inds. - Quaterly Results 22 May, 3:19 PM Sun Pharma Inds. - Quaterly Results 22 May, 3:19 PM Sun Pharma Inds. - Quaterly Results 22 May, 3:19 PM Sun Pharmaceutical Industries informs about acquisition 4 May, 3:15 PM

Sun Pharma Inds. Stock Price Analysis and Quick Research Report. Is Sun Pharma Inds. an attractive stock to invest in?

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Sun Pharma Inds. and its performance over the period of time. Sun Pharma Inds. stock price today is Rs 1767.2.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Sun Pharma Inds. cash from the operating activity was Rs -292.42 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Sun Pharma Inds. has a Debt to Equity ratio of 0.4662 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Sun Pharma Inds. , the EPS growth was 69.0522 % which is good for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Sun Pharma Inds. has OPM of 27.1262337134535 % which is a good sign for profitability.
     
  • ROE: Sun Pharma Inds. have a average ROE of 12.049 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
     
  • Share Price: - The current share price of Sun Pharma Inds. is Rs 1767.2. One can use valuation calculators of ticker to know if Sun Pharma Inds. share price is undervalued or overvalued.
Last Updated on:
Brief about Sun Pharma Inds.

Sun Pharmaceutical Industries Ltd. Financials: Check Share Price, Balance Sheet, Annual Report and Quarterly Results for Company Analysis

Sun Pharmaceutical Industries Ltd. is a leading pharmaceutical company in India, providing a wide range of products and services to its customers. In this article, we will analyze Sun Pharmaceutical Industries Ltd. from a stock market perspective. We will cover various topics such as share price, balance sheet, annual report, dividend, quarterly result, stock price, price chart, news, concall, transcripts, investor presentations, promoters, and shareholders.

Sun Pharmaceutical Industries Ltd. Share Price:

The share price of Sun Pharmaceutical Industries Ltd. is an important indicator of investor sentiment towards the company. The share price is influenced by various factors, such as the company's financial performance, global economic conditions, and market sentiment. Investors can use our pre-built screening tools to analyze Sun Pharmaceutical Industries Ltd.'s share price and identify any trends or patterns. Sun Pharmaceutical Industries Ltd.'s share price has been on an upward trend over the past few years, reflecting the company's strong financial performance and growth prospects.

Sun Pharma Share Price Introduction

Sun Pharma is a well-known company that makes medicines and other health-related products. This company plays a big part in helping people stay healthy. If you are curious about how much Sun Pharma's shares are worth right now, you can find this information in the share price section mentioned above the page. This section is useful because it shows the latest price of Sun Pharma's shares and also provides details like the highest and lowest share prices in the last 52 weeks and the highest and lowest prices of the day. This can help you understand how the value of Sun Pharma's shares changes over time.

Detailed Look at Sun Pharma Share Price

For anyone wanting to know more about Sun Pharma’s shares, the share price section above the page offers a lot of detailed information. It tells you about the highest and lowest prices that Sun Pharma's shares have been sold for in the past year, known as the 52-week high and low. You can also find out the highest and lowest share prices for today. This kind of detailed info is very helpful for understanding the range within which Sun Pharma's share price moves, giving a good overview of its performance in the stock market.

Sun Pharma Share Price Performance Overview

Keeping an eye on Sun Pharma's performance is important for many people, and the share price section mentioned above the page can help with this. In this section, you'll find a chart that shows how Sun Pharma's share price has changed over time. This includes the performance over short periods like one week, one month, six months, as well as longer periods like one year, three years, and five years. By looking at this chart, you can understand the trends in Sun Pharma's share price, like if it's been going up or down, and how it's been performing overall.

More Insights on Sun Pharma Share Price

If you're looking for an in-depth look at Sun Pharma's share price, the share price section above the page is the right place to start. This section doesn't just tell you the current price of Sun Pharma's shares; it provides a comprehensive summary that can offer a lot of insight. For example, by looking at the 52-week high and low, you can see the widest range the share price has moved in the past year. Also, the share price chart in this section shows how the company's shares have done over various time frames, such as one week, one month, six months, one year, three years, and five years. This gives you a better understanding of Sun Pharma's share price trends and performance over time.

Sun Pharmaceutical Industries Ltd. Balance Sheet:

Sun Pharmaceutical Industries Ltd.'s balance sheet provides crucial information about its financial health. The company's assets include fixed assets, investments, and other assets. Liabilities include borrowings, trade payables, and other liabilities. Equity includes share capital, reserves, and surplus. Investors can use our pre-built screening tools to analyze Sun Pharmaceutical Industries Ltd.'s balance sheet and identify any red flags. The company's balance sheet has remained strong over the years, with a healthy mix of assets and liabilities.

The Standalone Balance Sheet of Sun Pharma is a good sign for the company as it shows that for its growth it is not taking on too much debt. In the earliest financial year ending March, 2020, its total liabilities stood at ?38, 747.21 crores which rose to ?41, 985.34 for the fiscal ending, March 2024 Thus, there is a gradual progress though cautiously over time.

Sun Pharma Reserves: Fluctuating Patterns

Sun Pharma total reserves were ?24,156.29 crores in March 2020 and reduced to ?23,454.47 crores in the following year, March 2024. This oscillation could be due to operational deficiencies as well as strategic developments which underpinned the company’s strategic capabilities.

Sun Pharma Debt: Rising Borrowings

The borrowings of Sun Pharma went high from ?1,256.69 crores in March 2020 to ? 11,036.01 crores in March 2024. The rising level of debt could be due to the company’s expansion in capital or need of operation, and thus various investors shall monitor the level of debt of Sun Pharma in the subsequent future.

Sun Pharma Assets: Stability in Operations

The carrying amount of Sun Pharma’s total assets was almost constant and it has increased very slightly to ?41,985.34 crores in the last three years, that is, by March 2024 from ?38,747.21 crores in March 2020. The company’s net block, however, came down slightly to ?7,736.74 crore in March 2024 suggesting a possibility of a cut on operational assets or capital expenditure.

This analysis is done on the Sun Pharma Standalone Balance Sheet. Such financial performance measures are useful in analyzing trends in the sector for investors who are keen to monitor the industry’s performance based on certain sectors.

Sun Pharmaceutical Industries Ltd. Annual Report:

Sun Pharmaceutical Industries Ltd. releases an annual report every year, which provides detailed information about the company's financial performance, strategic initiatives, and future plans. The annual report includes a letter from the Chairman, financial statements, and management discussion and analysis. Investors can download Sun Pharmaceutical Industries Ltd.'s annual report from our website and use it to make informed investment decisions. The annual report provides valuable insights into the company's operations and financial performance.

Sun Pharmaceutical Industries Ltd. Dividend:

Sun Pharmaceutical Industries Ltd. regularly pays dividends to its shareholders. Dividends are a portion of the company's profits distributed to shareholders. Investors can use our pre-built screening tools to track Sun Pharmaceutical Industries Ltd.'s dividend history and dividend yield. The company has a consistent track record of paying dividends to its shareholders, which is a positive sign for long-term investors.

Sun Pharmaceutical Industries Ltd. Quarterly Results:

Sun Pharmaceutical Industries Ltd. releases its quarterly results every three months. The quarterly results provide information about the company's revenue, earnings, and expenses. Investors can use our pre-built screening tools to analyze Sun Pharmaceutical Industries Ltd.'s quarterly results and identify any trends or patterns. The quarterly results are an important indicator of the company's financial health and performance.

Sun Pharmaceutical Industries Ltd. Stock Price:

Sun Pharmaceutical Industries Ltd.'s stock price is affected by various factors, such as the company's financial performance, global economic conditions, and market sentiment. Investors can use our pre-built screening tools to track Sun Pharmaceutical Industries Ltd.'s stock price and identify potential buying opportunities. The stock price of Sun Pharmaceutical Industries Ltd. has been on an upward trend over the past few years, reflecting the company's strong financial performance and growth prospects.

Sun Pharmaceutical Industries Ltd. Price Chart:

A price chart provides a visual representation of a company's stock price over a period of time. Investors can use our pre-built screening tools to analyze Sun Pharmaceutical Industries Ltd.'s price chart and identify any trends or patterns. The price chart shows that the stock price of Sun Pharmaceutical Industries Ltd. has been on an upward trend over the past few years, reflecting the company's strong financial performance and growth prospects.

Sun Pharmaceutical Industries Ltd. News:

Keeping up to date with the latest news about Sun Pharmaceutical Industries Ltd. is important for investors. Our website provides the latest news about Sun Pharmaceutical Industries Ltd. from various sources, such as financial news websites and social media. Investors can use this information to make informed investment decisions.

Sun Pharmaceutical Industries Ltd. Concall:

Sun Pharmaceutical Industries Ltd. holds conference calls with analysts and investors to discuss its financial performance and future plans. Investors can listen to Sun Pharmaceutical Industries Ltd.'s concall and use the information provided to make informed investment decisions. Our website provides information about upcoming concalls and links to listen to past concalls.

Sun Pharmaceutical Industries Ltd. Transcripts:

Sun Pharmaceutical Industries Ltd.'s concall transcripts are available on our website. Investors can download the transcripts and use them to analyze the company's financial performance and future plans. The transcripts provide valuable insights into the company's operations and financial performance.

Sun Pharmaceutical Industries Ltd. Investor Presentations:

Sun Pharmaceutical Industries Ltd. provides investor presentations on its website. These presentations provide information about the company's financial performance, strategic initiatives, and future plans. Investors can download Sun Pharmaceutical Industries Ltd.'s investor presentations from our website and use them to make informed investment decisions. The investor presentations provide valuable insights into the company's operations and financial performance.

Sun Pharmaceutical Industries Ltd. Promoters:

Promoters are individuals or entities that have a significant stake in a company. Sun Pharmaceutical Industries Ltd.'s promoters include various entities that hold a significant stake in the company. Investors can use our pre-built screening tools to analyze Sun Pharmaceutical Industries Ltd.'s promoter holdings and identify any potential conflicts of interest. Sun Pharmaceutical Industries Ltd.'s promoter holdings are relatively stable, which is a positive sign for long-term investors.

Sun Pharmaceutical Industries Ltd. Shareholders:

Sun Pharmaceutical Industries Ltd. has a large number of shareholders, including institutional and individual investors. Investors can use our pre-built screening tools to analyze Sun Pharmaceutical Industries Ltd.'s shareholder base and identify any potential risks or opportunities. Sun Pharmaceutical Industries Ltd.'s shareholder base is diverse, which is a positive sign for long-term investors.

Sun Pharmaceutical Industries Ltd. Premium Features:

Our website provides premium features tools such as DCF Analysis, BVPS Analysis, Earnings multiple approaches, and DuPont analysis. These tools can help investors make better investment decisions by providing more detailed insights into the company's financial performance and valuation.

Sun Pharmaceutical Industries Limited ROCE

Sun Pharmaceutical Industries Limited is a leading pharmaceutical company. Return on Capital Employed (ROCE) is an important financial ratio that helps investors understand how efficiently a company is utilizing its capital. The ROCE of Sun Pharmaceutical Industries Limited can be found in the financials table or ratio section above.

Sun Pharmaceutical Industries Limited EBITDA

EBITDA, or Earnings Before Interest, Taxes, Depreciation, and Amortization, is a key metric for analyzing a company's profitability. Sun Pharmaceutical Industries Limited's EBITDA can be found in the financials table or ratio section above.

Sun Pharmaceutical Industries Limited DPS

DPS, or Dividends Per Share, is an important factor for investors interested in dividend income from a company. The DPS of Sun Pharmaceutical Industries Limited can be found in the financials table or ratio section above.

Sun Pharmaceutical Industries Limited EPS

EPS, or Earnings Per Share, provides insights into a company's profitability on a per-share basis. The EPS of Sun Pharmaceutical Industries Limited can be found in the financials table or ratio section above.

Please note that detailed data for these ratios can be obtained in the above financials table or ratio section.

Sun Pharma Revenue Analysis for Q2 FY25

The company’s consolidated net sales rose to Rs 5,127.71 crore in the quarter ended September 2024, according to the first quarter results for the financial year ending in March 2025. Sequentially, this has increased by 0.6% from Rs 5,096.21 crore in Q2 FY24 and while it is a decent rise of 14% from Rs 4,498.07 crore in Q1 FY25 which is indicative of improvement in demand for pharma products.

The trend of Operating profit of Sun Pharma  for Q2 FY25

Its operating profit for the quarter ended 30-September-2021 was Rs 1,210.29 crore, down 12% from Rs 1,376.93 crore in the same quarter last year. Nonetheless, compared to Rs 761.07 crore in Q1 FY25, the operating profit was better, mainly due to low operating costs.

Sun Pharma Results of Profit and Its EPS Journey for Q2 FY25

PAT of the company for the second quarter of FY25 was at Rs 863.29 crore which had reduced from Rs 888.63 crore in the second quarter of FY24. This is nonetheless a considerable gain compared to Rs 237.82 crore in the Q1 of FY25. Net sales and other operating revenues increased by 13% YoY and adjusted EPS for Q2 FY25 was at Rs 3.60 as against Rs 3.70 in Q2 FY24.

Expense and Other Income Analysis on Sun Pharma for Q2 FY25

Other income for the Q2 FY25 has increased to Rs 214.63 crore compared with Rs 115.93 crore for Q2 FY24. Interest expenses rose to Rs 243.75 crore in the quarter ending December 2022 from Rs 193.63 crore in the same period of the year before, which hurts profitability.

These numbers are based on an analysis of the company’s first-quarter standalone numbers. NSE and BSE indices on the pharmaceutical sector may be observed by investors for other industry growth and trends.

Read More
X